Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo.
Intracerebral hemorrhage represents stroke characterized by formation and expansion of hematoma within brain parenchyma. Blood-derived factors released from hematoma are considered to be involved in poor prognosis of this disorder. We previously reported that thrombin, a blood-derived serine protease, induced cytotoxicity in the cerebral cortex and the striatum in organotypic slice cultures, which depended on mitogen-activated protein kinase (MAPK) pathways. Here we investigated the mechanisms of thrombin cytotoxicity in the striatum in vivo. Thrombin microinjected into the striatum of adult rats induced neuronal death and microglial activation around the injection site. Neuronal loss without any sign of nuclear fragmentation was observed as early as 4 h after thrombin injection, which was followed by gradual neuronal death exhibiting nuclear fragmentation. Thrombin-induced damage assessed at 72 h after injection was partially but significantly reduced by concomitant administration of inhibitors of MAPK pathways. Activation of extracellular signal-regulated kinase (ERK) and p38 MAPK in response to thrombin was verified by Western blot analysis. Moreover, phosphorylated ERK and p38 MAPK were localized prominently in reactive microglia, and inhibition of microglial activation by minocycline attenuated thrombin-induced damage, suggesting that reactive microglia were responsible for thrombin-induced neuronal death. Thus, MAPK pathways and microglial activation may serve as therapeutic targets of pathogenic conditions associated with hemorrhagic stroke.
Fujimoto
S
S
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Katsuki
H
H
Ohnishi
M
M
Takagi
M
M
Kume
T
T
Akaike
A
A
D000818:Animals; D039481:CD11b Antigen / Q000378:metabolism; D002452:Cell Count; D003342:Corpus Striatum / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007839:Functional Laterality; D006490:Hemostatics / Q000633:toxicity*; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000201:enzymology; D020258:Neurotoxicity Syndromes / Q000209:etiology*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013917:Thrombin / Q000633:toxicity*; D013997:Time Factors
D039481:CD11b Antigen; D004791:Enzyme Inhibitors; D006490:Hemostatics; D020928:Mitogen-Activated Protein Kinases; D013917:Thrombin; D010751:Phosphopyruvate Hydratase